Rituximab and autologous stem cell transplantation for malignant lymphoma after liver transplantation.
Sánchez-González
B
B
Fernández-Abellán
P
P
Garcia Garay
M C
MC
Villarrubia
B
B
Palmero
M F
MF
Rivas
C
C
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016031:Liver Transplantation / Q000009:adverse effects*; D008223:Lymphoma / Q000209:etiology* / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous / Q000379:methods*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D016572:Cyclosporine